Monday, 4 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 04 May 2026
News

Blast from the past heads to PBAC

Posted 4 May 2026

The PBAC will be haggling over price in its May Intracycle Meeting, and revisiting a drug it deferred four years ago.

Pfizer is headed back to the Committee with a revised pricing proposal for tyrosine kinase inhibitor Tukysa in Stage IV HER-2+ breast cancer after failing to come to an agreement with the Government following a positive PBAC recommendation in November last year, with the listing process currently marked as 'ceased'

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (8)

Sales & Customer Relations (10)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Other (6)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.